Morgan Stanley
CSCI

Morgan Stanley’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Morgan Stanley’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$1.7K – 8421
2025
Q2 		$1.7K Sell
500
-2
-0.4% -$7 ﹤0.01% 7257
2025
Q1 		$1.42K Buy
502
+102
+26% +$301 ﹤0.01% 7237
2024
Q4 		$1.11K Buy
+400
New +$1.3K ﹤0.01% 7261
2024
Q3 		– Sell
-10
Closed -$44 – 8046
2024
Q2 		$44 Sell
10
-4,035
-100% -$30.8K ﹤0.01% 7542
2024
Q1 		$35.4K Sell
4,045
-3,995
-50% -$30.8K ﹤0.01% 6337
2023
Q4 		$59.8K Buy
8,040
+4,020
+100% +$29.7K ﹤0.01% 6328
2023
Q3 		$40.2K Sell
4,020
-33
-0.8% -$366 ﹤0.01% 6257
2023
Q2 		$41.7K Buy
4,053
+12
+0.3% +$137 ﹤0.01% 6282
2023
Q1 		$42.3K Buy
4,041
+438
+12% +$5.83K ﹤0.01% 6338
2022
Q4 		$45.8K Buy
3,603
+140
+4% +$2.08K ﹤0.01% 6333
2022
Q3 		$53K Buy
3,463
+437
+14% +$8.38K ﹤0.01% 6385
2022
Q2 		$59K Buy
3,026
+2,466
+440% +$61.7K ﹤0.01% 6543
2022
Q1 		$20K Buy
560
+343
+158% +$12.3K ﹤0.01% 7158
2021
Q4 		$7K Sell
217
-41
-16% -$2.16K ﹤0.01% 7580
2021
Q3 		$19K Sell
258
-33
-11% -$2.34K ﹤0.01% 7121
2021
Q2 		$25K Sell
291
-120
-29% -$11.4K ﹤0.01% 6930
2021
Q1 		$47K Sell
411
-4,867
-92% -$540K ﹤0.01% 6377
2020
Q4 		$224K Sell
5,278
-5,962
-53% -$221K ﹤0.01% 5535
2020
Q3 		$395K Buy
11,240
+2,869
+34% +$127K ﹤0.01% 4755
2020
Q2 		$671K Sell
8,371
-204
-2% -$18.7K ﹤0.01% 4444
2020
Q1 		$439K Buy
8,575
+898
+12% +$81.9K ﹤0.01% 4454
2019
Q4 		$699K Buy
7,677
+365
+5% +$34K ﹤0.01% 4747
2019
Q3 		$753K Buy
7,312
+434
+6% +$94K ﹤0.01% 4466
2019
Q2 		$2.03M Sell
6,878
-145
-2% -$51.1K ﹤0.01% 3754
2019
Q1 		$3.27M Sell
7,023
-51
-0.7% -$19.8K ﹤0.01% 3128
2018
Q4 		$2.08M Buy
7,074
+3,308
+88% +$791K ﹤0.01% 3731
2018
Q3 		$656K Buy
3,766
+1,275
+51% +$234K ﹤0.01% 4829
2018
Q2 		$487K Buy
2,491
+1,086
+77% +$200K ﹤0.01% 5121
2018
Q1 		$205K Buy
1,405
+557
+66% +$109K ﹤0.01% 5456
2017
Q4 		$200K Buy
848
+484
+133% +$101K ﹤0.01% 5405
2017
Q3 		$75K Buy
364
+19
+6% +$3.5K ﹤0.01% 5656
2017
Q2 		$34K Buy
345
+8
+2% +$1.27K ﹤0.01% 5960
2017
Q1 		$102K Buy
337
+28
+9% +$8.24K ﹤0.01% 5593
2016
Q4 		$112K Buy
309
+98
+46% +$36.5K ﹤0.01% 5536
2016
Q3 		$73K Buy
211
+129
+157% +$45.2K ﹤0.01% 5437
2016
Q2 		$26K Buy
82
+53
+183% +$19.1K ﹤0.01% 5764
2016
Q1 		$10K Buy
29
+21
+263% +$6.92K ﹤0.01% 6138
2015
Q4 		$4K Buy
+8
New +$5.02K ﹤0.01% 6420
2015
Q3 		– Hold
0
– – – 6742
2015
Q2 		– Sell
-1
Closed -$4.21K – 6582
2015
Q1 		$6K Sell
1
-8
-89% -$45.9K ﹤0.01% 6313
2014
Q4 		$53K Buy
9
+8
+800% +$67.2K ﹤0.01% 5802
2014
Q3 		$15K Hold
1
– – ﹤0.01% 6094
2014
Q2 		$14K Sell
1
-2
-67% -$22.3K ﹤0.01% 6111
2014
Q1 		$33K Hold
3
– – ﹤0.01% 5845
2013
Q4 		$46K Buy
3
+2
+200% +$26.6K ﹤0.01% 5622
2013
Q3 		$19K Hold
1
– – ﹤0.01% 5285
2013
Q2 		$24K Buy
+1
New +$19K ﹤0.01% 5264

Other funds holding CSCI

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley's CSCI Position: Q3 2025 in Review

Morgan Stanley sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2025, closing a stake of 500 shares — an estimated $1.7K sold.

Morgan Stanley first reported a position in CSCI in Q2 2013 and held it in 46 quarters. The position peaked at $3.27M in Q1 2019. 2 funds tracked by Wall St. Rank hold CSCI as of Q3 2025.

  • Morgan Stanley reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2025 after selling out during the quarter.
  • Morgan Stanley sold 500 COSCIENS Biopharma Inc. Common Stock shares in Q3 2025, an estimated $1.7K.
  • Morgan Stanley first reported a position in COSCIENS Biopharma Inc. Common Stock in Q2 2013 and held it in 46 quarters.
  • Morgan Stanley's COSCIENS Biopharma Inc. Common Stock position peaked at $3.27M in Q1 2019.
  • 2 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2025.

Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.